1		Recovery from Amblyopia in Adulthood: A Meta-Analysis
2		
3 4	Running title	e: Recovery from Amblyopia in Adulthood
4 5 6 7	Authors:	Madison P. Echavarri-Leet ¹ ; Hannah H. Resnick, MD, MPhil ^{2,3} ; Daniel A. Bowen ^{1,4} ; Deborah Goss ⁵ ; Mark F. Bear, PhD ¹ ; Eric D. Gaier, MD, PhD ^{1,3,4}
8 9 10 11 12 13 14	Affiliations:	 ¹ Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA ² Department of Pediatrics, Massachusetts General Hospital, Boston, MA ³ Harvard Medical School, Boston, MA ⁴ Department of Ophthalmology, Boston Children's Hospital, Boston, MA ⁵ Howe Library, Massachusetts Eye and Ear, Boston, MA
15 16 17 18 19 20 21 22	Correspond	ence: Eric D. Gaier, MD PhD Department of Ophthalmology Boston Children's Hospital 300 Longwood Ave Boston, MA 02115 Phone: 617-355-6401 Email: eric.gaier@childrens.harvard.edu
22 23 24 25 26 27	Funding:	 MPL: NIH F31 EY033996 MFB: NIH R01 EY029245, RPB #42894, Picower Neurological Disorder Research Fund EDG: NIH K08 EY030164, Children's Hospital Ophthalmology Foundation
28 29 30 31 32 33 34		nterest statement: MFB: Luminopia, Inc. (scientific advisor, equity) EDG: Luminopia, Inc. (scientific advisor, equity, patent), Stoke Therapeutics Inc. (consultant) Amblyopia, vision loss, retinal ganglion cells, neuroplasticity
35		

36 Abstract

37 Purpose:

38 The effectiveness of traditional amblyopia therapies is largely restricted to childhood.

39 However, recovery in adulthood is possible following removal or vision-limiting disease

40 of the fellow eye. Study of this phenomenon is currently limited to isolated case reports

41 and a few case series, with reported incidence ranging from 19-77% ¹⁻⁵. We set out to

42 accomplish two distinct goals: (1) define the incidence of clinically meaningful recovery

43 and (2) elucidate the clinical features associated with greater amblyopic eye gains.

44 Methods:

45 A systematic review of 3 literature databases yielded 23 reports containing 109 cases of

46 patients \geq 18 years old with unilateral amblyopia and vision-limiting fellow eye pathology.

47 Results:

Study 1 revealed 25/42 (59.5%) of adult patients gained ≥2 logMAR lines in the 48 49 amblyopia eye after FE vision loss. The overall degree of improvement is clinically 50 meaningful (median 2.6 logMAR lines). Study 2 showed that for cases with amblyopic eye visual acuity improvement, recovery occurs within 12 months of initial loss of fellow 51 52 eye vision. Regression analysis revealed that younger age, worse baseline acuity in the 53 amblyopic eye, and worse vision in the fellow eye independently conferred greater gains 54 in amblyopic eye visual acuity. Recovery occurs across amblyopia types and fellow eye 55 pathologies, although disease entities affecting fellow eye retinal ganglion cells 56 demonstrate shorter latencies to recovery.

57 Conclusions:

58 Amblyopia recovery after fellow eye injury demonstrates that the adult brain harbors the

59 neuroplastic capacity for clinically meaningful recovery, which could potentially be

60 harnessed by novel approaches to treat adults with amblyopia.

61

62 Introduction

Amblyopia is a prevalent visual disorder resulting from abnormal visual experience during early development⁶⁻⁸. The long-standing and current treatment standard involves occlusion via patching or pharmacologic cycloplegia of the fellow eye (FE). While most children with amblyopia experience visual acuity (VA) gains in the amblyopic eye (AE) following standard therapy, improvement is often incomplete and restricted to cases where therapy is initiated before age 8^{9, 10}. As such, treatment of amblyopia is widely considered futile in adults in routine ophthalmic practice.

There is extensive evidence that at least partial recovery from amblyopia can 70 occur in experimental animal models late in the critical period (when simple occlusion-71 type interventions fail) and beyond¹¹⁻¹⁴. For instance, experiments in mice and cats 72 show that temporary inactivation of retinal ganglion cell (RGC) activity in both eyes or 73 74 just the FE establishes conditions that enable the rapid and durable recovery from amblyopia¹⁵⁻¹⁷. This intervention is effective at ages when reversed occlusion 75 (analogous to patch therapy in humans) fails to promote sustained recovery^{16, 17}. 76 77 Enucleation and retinal lesioning similarly promote recovery in visual cortical responses to stimulation of AEs of adult cats, monkeys, and mice¹⁸⁻²². Direct limitation of RGC 78 79 activity is a common theme distinguishing the interventions that successfully drive 80 recovery in older animals from those that do not. Thus, the pre-clinical, experimental

basis for amblyopia recovery in adulthood is strong and broad, but comprehensive
supporting evidence in humans is needed.

Analogous observations of recovery from amblyopia triggered in human patients 83 who suffer vision-limiting FE disease or loss spans decades of clinical literature. To 84 85 date, there have been 5 dedicated studies examining amblyopia recovery following FE 86 vision loss; 3 focus on specific FE disorders (ischemic optic neuropathy¹, age-related macular degeneration², uveal melanoma³), and 2 include all causes of FE visual loss^{4, 5}. 87 Additionally, numerous isolated reports describe the clinical courses of 1-3 patients in 88 89 various clinicopathologic contexts. Despite this substantial literature, key features of this important phenomenon, which may hold the key to reversal of amblyopia in adulthood, 90 91 remain undefined. To begin to fill this knowledge gap, we integrated and analyzed all available 92 clinical descriptions of AE VA recovery in the context of FE disease in adults. We aimed 93 94 to (1) describe the prevalence and magnitude of recovery and (2) answer whether

specific clinical metrics influence the magnitude of AE VA gains. We tested the
hypotheses that direct FE RGC injury and absence of strabismus would confer greater

97 AE VA improvement.

98

99 Methods

100 Database Search

101 A systematic search of PubMed (1946-), Embase (1947-), and Web of Sciences 102 Core Collection (1900-) databases was conducted using combinations of the following 103 key words: "amblyopia", "recov-", "revers-", "loss", "injury", "visual impairment", "fellow",

104	"fixating", "dominant", "good", "contralateral", "eye". Initial searches were designed and
105	executed by HHR and DG. Final searches were run on December 21st, 2021. A total of
106	1660 unique abstracts (deduplication from 2925 using Endnote X7.8) were returned.
107	Covidence software (https://www.covidence.org) was used to manage the review
108	process. Each unique abstract was screened by two independent team members, and
109	conflicts were resolved by EDG. PRISMA guidelines were used for documentation ²³ .
110	
111	Article inclusion
112	Abstracts were screened based on the following inclusion criteria: cases of
113	human adults (≥18 years of age) with amblyopia and FE vision loss; provides individual
114	patient-level data; provides at least 2 AE VA measurements at different timepoints.
115	
116	Article exclusion
117	Articles focused on basic neuroscience/experimental techniques/interventions
118	were excluded. Reports that were not published, were not primary articles (e.g., book
119	chapters, lectures, abstracts, presentations, reviews) or were not available in English
120	were excluded.
121	
122	Literature analysis:
123	After abstract screening, 35 articles were reviewed in detail, and 17 ultimately
124	met all inclusion and exclusion criteria. Bibliographies of each included report were

reviewed for additional potentially relevant reports not captured in our database

searches. All referenced studies were collected and reviewed in detail, yielding 6

- additional reports meeting criteria. In total, 23 reports (comprised of 109 unique cases)
- were included for analysis (Supplemental Figure 1).
- 129
- 130 *Data Extraction:*
- 131 Each report was comprehensively and systematically examined. We extracted all
- parameters of interest for further analysis for each patient when available, including:
- Initial AE VA before the injury, if available, or else at the time of first evaluation
 after FE vision loss.
- 135 Best measured AE VA after FE vision loss.
- Time interval from FE visual loss to best AE VA measurement (in months). If the
- time fell in the middle of the month or the exact length of time could not be
- determined, the time was rounded to the next month. If months were not
- provided for each timepoint, the difference in years was multiplied by 12. Times
- 140 less than 1 month were rounded to one month.
- 141 FE VA nadir, defined as the worst reported FE VA after onset of FE visual loss
- Patient age at the time of FE loss; age was binned as 18-40, 41-60, and ≥61
- 143 years for analysis.
- 144 All VA measures were converted to the logarithm of the minimum angle of resolution
- 145 (logMAR) scale and rounded to the nearest 0.02 unit (1 letter). AE VA logMAR lines of
- 146 improvement was calculated from best-initial AE VA logMAR values.

147

148 Analysis:

149 We conducted 2 separate goal-directed studies. Study 1 aimed to determine the incidence and magnitude of AE VA improvement. To minimize the influence of reporting 150 151 bias, only series reporting consecutive subjects with patient-level data within a defined 152 study period (agnostic to whether recovery occurred for each individual patient) were 153 included (42 cases, 3 series). Study 2 aimed to describe the clinical features associated 154 with AE VA gains and thus focused on only cases with measurable (>0.0 logMAR) improvement (101 cases, 23 reports). Among these, 55 cases specified FE VA 155 156 measurements (to assess the influence of FE visual loss magnitude), 37 cases 157 specifically reported on the presence/absence of strabismus (for segregation by 158 amblyopia type), 38 cases had a clearly documented cause of FE vision loss (for 159 segregation by direct RGC involvement), and 80 cases specified the timeline from FE 160 vision loss to key AE VA measurement in follow-up (to assess temporal rate of recovery) (Figure 1). 161

162

163 *Statistics:*

Normality of data was assessed with the Kolmogorov-Smirnov test. Direct 164 165 comparisons between two normally distributed groups employed a two-tailed t-test, 166 whereas those involving one or more groups that were not normally distributed 167 employed a Mann-Whitney test. In the case of comparing initial to best AE VA values 168 (which were not normally distributed) a Wilcoxon matched-pairs test was used to assess 169 whether changes in individual case AE VA values changed significantly. A univariate 170 multiple regression was performed (SPSS, IBM, Armonk, NY) with input variables: age, 171 baseline AE VA, FE VA nadir. The output variable was AE VA (logMAR lines) of

172	improvement. A modified Breusch-Pagan test determined that the data were
173	heteroskedastic (p =0.006). To control for this, robust standard errors calculation (HC3)
174	was used in calculations of <i>p</i> -values in the linear regression. Bias in the linear model
175	based on whether data came from a paper with a small sample size (\leq 3 cases) or a
176	larger sample size (>3 cases) was assessed by comparing the effect size of each of the
177	independent variables ^{24 25} . The threshold for statistical significance was set at p <0.05 in
178	all cases.
179	
180	Results:

181 STUDY 1: Incidence of clinically meaningful recovery

Of the 109 reports revealed by our review, 23 were isolated case reports or small (≤3 cases) series. To mitigate the effects of reporting bias through underrepresentation of cases without recovery, we analyzed the 42 cases originating from 3 reports containing >3 cases that were agnostic to the occurrence of recovery and included patient-level data.

Among these 42 cases, the median change in AE VA was 2.60 logMAR lines [IQR:0.95-4.00] . Eight (19.0%) had no AE VA improvement. Among the remaining cases, 34 (81.0%) had measurable AE VA improvement, 32 (76.2%) gained \geq 1 logMAR line, 25 (59.5%) gained \geq 2 logMAR lines, and 21 (50.0%) cases gained \geq 3 lines (Figure 2). These findings demonstrate a high incidence of clinically meaningful recovery among adults after loss of vision in the FE.

193

194 STUDY 2: Features influencing amblyopic eye recovery

195	To identify clinical factors associated with greater AE VA improvement after FE
196	vision loss, we narrowed the 109 cases in our review to the 101 who demonstrated AE
197	VA gains. Among these, median initial AE VA was 1.00 logMAR [IQR: 0.50-1.00)]. The
198	median best AE VA following FE vision loss was 0.22 logMAR [IQR: 0.10-0.42] (Figure
199	3A, B). The median change in AE VA following loss of vision in the FE was 5.0 logMAR
200	lines of improvement, which was significant via a Wilcoxon matched-pairs test
201	(<i>p</i> <0.0001). 84/101 (83.2%) of patients exhibited ≥3.0 logMAR lines of improvement
202	(Figure 3C). Median time from FE vision loss to maximum AE VA was 12.0 months
203	[IQR: 6.25-24.00] (Figure 3D), though this likely reflects a frequent timepoint for
204	scheduled follow up.
205	
206	Linear modeling of clinical feature influence on recovery
206 207	Linear modeling of clinical feature influence on recovery A linear model was constructed to assess the relationship between binned age,
207	A linear model was constructed to assess the relationship between binned age,
207 208	A linear model was constructed to assess the relationship between binned age, initial AE VA, and FE VA nadir with logMAR lines of improvement for the AE following
207 208 209	A linear model was constructed to assess the relationship between binned age, initial AE VA, and FE VA nadir with logMAR lines of improvement for the AE following FE vision loss. This analysis was restricted to the 55 available cases with recorded FE
207 208 209 210	A linear model was constructed to assess the relationship between binned age, initial AE VA, and FE VA nadir with logMAR lines of improvement for the AE following FE vision loss. This analysis was restricted to the 55 available cases with recorded FE VA data. Younger age was associated with greater AE VA gains with an effect size of
207 208 209 210 211	A linear model was constructed to assess the relationship between binned age, initial AE VA, and FE VA nadir with logMAR lines of improvement for the AE following FE vision loss. This analysis was restricted to the 55 available cases with recorded FE VA data. Younger age was associated with greater AE VA gains with an effect size of 1.7 logMAR lines for each younger age bin (p =0.002). More severe amblyopia was
207 208 209 210 211 212	A linear model was constructed to assess the relationship between binned age, initial AE VA, and FE VA nadir with logMAR lines of improvement for the AE following FE vision loss. This analysis was restricted to the 55 available cases with recorded FE VA data. Younger age was associated with greater AE VA gains with an effect size of 1.7 logMAR lines for each younger age bin (p =0.002). More severe amblyopia was associated with greater AE VA gains with an effect size of 4.9 logMAR lines of
207 208 209 210 211 212 213	A linear model was constructed to assess the relationship between binned age, initial AE VA, and FE VA nadir with logMAR lines of improvement for the AE following FE vision loss. This analysis was restricted to the 55 available cases with recorded FE VA data. Younger age was associated with greater AE VA gains with an effect size of 1.7 logMAR lines for each younger age bin (p =0.002). More severe amblyopia was associated with greater AE VA gains with an effect size of 4.9 logMAR lines of improvement (p <0.001). Worse FE VA nadir correlated with greater AE VA gains, with

216 Hypothesis-driven categorical clinical feature influence on recovery

217	Amblyopia etiology was unavailable for 64 patients, so they were not included in
218	this analysis. 18 patients had a history or presence of strabismus, and 19 patients did
219	not. There was no significant difference in AE VA improvement between those with
220	(median: 4.00 [IQR: 1.95-8.40]) versus those without (median: 3.90 [IQR: 2.20-6.00])
221	strabismus (<i>p</i> >0.9; Mann-Whitney test). (Figure 5A).
222	Of the 101 cases found through our systematic literature search, 38 had clear
223	documentation relating to the cause of FE vision loss where direct involvement of RGCs
224	could be ascertained. Of those 38 cases, 22 cases of FE vision loss with RGC
225	involvement and 16 cases without RGC involvement. There was no significant
226	difference in AE VA improvement between cases with (median: 3.00 [IQR: 1.80- 8.20)])
227	and without (median: 4.00 [IQR: 3.00-8.20]) RGC injury (<i>p</i> >0.3, Mann-Whitney test).
228	Comparing rate of recovery, those with RGC injury saw faster improvement in AE VA
229	(median: 8 months [IQR: 2-19]) than those without (median: 12 months [IQR: 12-41];
230	<i>p</i> =0.0124, Mann-Whitney test) (Figure 5B, C)
231	
232	Post-hoc assessment of study bias:
233	Our systematic review returned reports that contained larger case series with >3
234	cases (n=5) and case reports/smaller case series (≤3 cases) (n=18). Because larger
235	case series contributed 78/101 (77.2%) cases, we asked whether this distribution could
236	influence the results. There was no significant difference between AE VA gains between
237	those contributed by larger case series (median: 4.80 [IQR: 3.00-7.00]) and small case

series/reports (median: 7.00 [IQR: 3.90-8.60]; *p*=0.098, Mann-Whitney test)

239 (Supplemental Figure 2A). Confidence intervals for each case series and the composite

240	of small series and isolated reports overlap the median of 5.0 logMAR lines of AE VA
241	improvement for the overall sample without systematic bias trends (Supplemental
242	Figure 2B). We assessed whether the linear clinical factors found to influence AE VA
243	improvement differed systematically across studies. There were no significant
244	differences in regression weights between groups (binned age Z=0.056, p>0.9; initial
245	AE VA Z=1.465, p>0.14=; FE VA nadir Z=0.704, p>0.4), suggesting neither report type
246	imparts measurable bias on regression weights for linear clinical factors. Thus, there
247	was no clear evidence of bias imparted by report type or size on the primary outcome
248	measure in Study 2.

249

250 Discussion

251 Although conventional occlusion therapy is not effective in adults with amblyopia, gains in AE VA following FE vision loss is common. Integration and analysis of reported 252 253 cases demonstrate that the adult visual system retains the capacity for plasticity 254 necessary for recovery from amblyopia. These results show that 60% of adults with 255 amblyopia who experience FE vision loss will gain at least 2 lines of AE VA. Amblyopia 256 treatment trials in children <8 years of age reporting an average of 2-3 logMAR lines of 257 improvement following 3-6 months of occlusion treatment suggest that the prevalence of recovery is substantial⁸. By comparison, only 25% of 13–17-year-olds (and 47% of 258 259 treatment naïve 13–17-year-olds) gain ≥ 2 lines of AE VA following 2-6 hours of daily 260 patching²⁶. While randomized control trials in adults are not available, this comparison 261 suggests that the rate of AE VA improvement seen after FE vision loss markedly 262 exceeds conventional occlusion therapy.

263 We focused our study of clinical factors on cases with some degree of AE VA improvement to avoid over-representation of recovered cases by inclusion of isolated 264 265 reports. In this sample, we found that improvement is generally observed within 12 266 months following FE vision loss, and further gains after this time point are less common. Most amblyopia is associated with anisometropia, strabismus, or both²⁷. A history of or 267 268 presence of strabismus did not influence the degree of AE VA recovery in our study despite more blunted gains²⁸ and higher rates of regression²⁹ in conventionally treated 269 270 strabismic compared to anisometropic amblyopia. Given that previous research 271 indicates that temporary inactivation of FE RGCs promotes recovery from amblyopic 272 rearing in mice and cats, we postulated that direct RGC involvement may be required to 273 enable the plasticity necessary to drive recovery in older age, but our results suggest 274 this is not necessarily the case^{15, 16}. We noted comparable rates of recovery in outer retinal disorders such as age-related macular degeneration² and uveal melanoma³ as 275 276 with ischemic optic neuropathy¹. FE injury directly involving RGC damage did not affect 277 the magnitude of AE VA gains but did confer a faster rate of recovery. Though the 278 current analyses focus on injuries involving damage to RGCs, future work could 279 potentially compare pre-retinal (e.g. corneal, lenticular) and retinal/optic nerve disorders. It is well-documented that the success of amblyopia treatment depends on 280 281 patient age, and that adults generally do not respond to conventional amblyopia treatment methods^{8, 10, 11, 30, 31}. Although our analysis was restricted to adult patients, we 282 were curious whether patient age at the time of FE loss would be a factor associated 283 284 with degree of AE VA improvements. Linear regression analysis showed that younger 285 age, greater severity of vision loss in the FE, and worse initial AE VA independently

influenced the degree of improvement in the AE VA. These results may be applied in
clinical contexts to prognosticate the degree of AE recovery in new cases of FE vision
loss.

Our study has several limitations, mainly stemming from factors inherent to the 289 290 nature of meta-analyses. The availability and reliability of data could not be controlled in 291 this systematic literature review spanning many decades, journals and report types. 292 Subgroup analyses and linear models engaged fractions of our sample because of inconsistencies in reported details between cases and reports, and thus there is some 293 294 susceptibility to bias within our sample. This underscores the importance of our post-295 hoc analysis, which demonstrated no systematic biases of report type on either the 296 primary outcome measure or the factors found to be influential through linear modeling. 297 Despite these inherent limitations, the relative infrequency of this clinical problem (owing 298 to a need for two separate ophthalmic conditions in each eye: amblyopia and vision-299 limiting FE pathology) necessitates meta-analysis as the only feasible means to test our 300 hypotheses. However, advancement of means to build and integrate large medical 301 databases could provide another means to study this phenomenon in the future, 302 provided that the minimal patient-level details such as laterality are available. The Bienenstock, Cooper, and Munro (BCM) theory of metaplasticity³² provides a 303 useful conceptual framework to understand how FE vision loss can drive AE recovery¹⁴. 304 305 The BCM theory posits that the threshold for cortical synaptic potentiation changes as a function of the history of integrated post-synaptic neuronal activity. In this clinical 306

307 context, the reduction in visual cortical activity following FE vision loss lowers the

308 plasticity threshold to enable potentiation of synapses serving the AE, ultimately

309 improving AE visual function. Of course, permanent FE vision loss is not a viable treatment approach. However, according to this theoretical model, even temporary 310 silencing of the FE may be sufficient to enable synapses serving the AE to grow in 311 312 strength and, importantly, maintain these improvements even when the FE activity 313 returns to normal. Understanding the molecular, cellular and circuitry contributions to metaplasticity^{14, 33-35} may lead to novel amblyopia therapies in adults. Experimental 314 315 elucidation of the relevant mechanisms through animal models will serve to refine potential therapeutic targets whereby the plasticity that enables recovery from 316 317 amblyopia in adulthood could one day be harnessed. 318 Acknowledgements: 319 320 Hui Li, PhD candidate in biostatistics at the Harvard T.H. Chan of Public Health, for statistical consultation. 321 322 323 Figure Legends: Figure 1: Inclusion criteria and case selection for Studies 1 and 2. 109 cases from 324 325 23 papers met our initial inclusion criteria. To determine the incidence of AE VA improvement following FE VA loss for Study 1, we only included papers that reported 326 both positive and negative results to minimize the influence of reporting bias. Only 3 of 327 328 the 23 papers reported negative and positive results; the remaining 20 papers only reported positive cases. Thus, only the 42 cases from these 3 papers were included in 329 330 Study 1. In Study 2, we focused only on cases where some degree of AE VA 331 improvement was observed. 101 cases from 23 papers met this criterion. Some

332	analyses within Study 2 were restricted to cases in which specific data were available:
333	time course to maximal AE (n=80), FE VA nadir (n=55), strabismus status (n=37), and
334	etiology of FE vision loss (n=38).
335	
336	Figure 2: Following fellow eye vison loss, the majority of adults improve visual
337	acuity in the amblyopic eye. (A) Three dedicated studies met our inclusion criteria for
338	the purposes of Study 1, with a similar incidence of recovery observed in each.
339	(B) Pie chart illustrating how many cases had various degrees of AE VA improvement.
340	
341	Figure 3: For most adult amblyopes who improve amblyopic eye visual acuity
342	following loss of vision in the fellow eye, recovery occurs within 12 months. (A)
343	Box plots depicting median logMAR VA (black line) at baseline (blue) and maximal AE
344	VA following FE vision loss (red) (**** p <0.0001). The top and bottom borders of the box
345	indicate quartiles, and whiskers indicate minimum and maximum values (n=101). (B)
346	Individual case data of baseline and maximal AE VA (n=101). (C) Violin plot depicting
347	the distribution of AE VA improvement for all cases (n=101). The red line depicts the
348	median, and blue lines depict quartiles. (D) Violin plot depicting the distribution of time
349	from FE vision loss to maximal AE VA (n=80). The red line depicts the median, and blue
350	lines depict quartiles.
351	
352	Figure 4: Linear modeling reveals younger age, worse initial amblyopic eye visual
353	acuity, and worse fellow eye visual acuity following vision loss are independently

354 associated with greater amblyopic eye visual acuity improvement. (A) Effect sizes

355	of significant factors identified by multiple linear regression using robust standard errors.
356	Bars represent 95% confidence intervals. (B) Mesh grids of predicted values and
357	calculated slope from the linear model segregated by age bins: 18-40 (left), 41-60
358	(center), 61+ (right). Individual case AE VA improvement values are represented by
359	black dots and lines connect to the plane of best fit.
360	
361	Figure 5: Testing the influence of categorical clinical features of amblyopia or
362	fellow eye vision loss on the degree of amblyopia eye visual acuity recovery. (A)
363	Box plots depicting median logMAR line VA improvement (black line) according to
364	strabismus status (ns p >0.9; Mann-Whitney test). Top and bottom borders of the boxes
365	indicate quartiles and whiskers indicate range. (B) Box plots depicting median logMAR
366	line VA improvement (black line) according to FE pathology involvement of retinal
367	ganglion cells (RGCs) (ns <i>p</i> >0.3; Mann-Whitney test). (C) Box plots depicting median
368	time to maximal AE VA (black line) according to FE pathology involvement of RGC (*
369	<i>p</i> =0.0124; Man-Whitney test).
370	
371	Supplemental Figure 1: Method for collection and inclusion of relevant reports
372	and cases.
373	A systematic search of PubMed (1946-), Embase (1947-), and Web of Sciences Core
374	Collection (1900-) databases was conducted and returned 2925 papers. After
375	deduplication, 1660 abstracts were screened by two members of the team for
376	relevance. 35 papers were sought for retrieval and the relevance was assessed based
377	on the article in its entirety. We ultimately determined that 17 of these papers met our

eligibility criteria for inclusion in the meta-analysis. Eligible papers then had their
individual bibliographies reviewed. Non-duplicate references were retrieved, and 39
additional sources were screened for relevance. 10 ultimately were reviewed in full, and
6 of these met eligibility criteria and were included in the final meta-analysis. In total 23
reports comprised of 109 cases were included. PRISMA guidelines were used for this
documentation ²³.

384

Supplemental Figure 2: Assessing potential bias in primary outcome measure 385 386 (logMAR lines of recovery) by report type. (A) AE VA (logMAR lines) improvement segregated by report type (ns p=0.098; Mann-Whitney test). Error bars indicate 95% 387 388 confidence interval. Black dotted line indicates the median ($y = 5.0 \log MAR$ lines of AE 389 VA improvement) for all cases, regardless of report type. (B) Forest plot comparing the median logMAR lines of AE VA improvement (black dots) with 95% confidence intervals 390 391 (error bars) for all case series containing >3 cases individually and pooled case reports 392 and case series containing ≤3 cases. The number of reported cases and authors for 393 each report of case series comprise the y-axis labels. Red dotted line (x = 5.0) indicates 394 the median logMAR lines of AE VA improvement for all cases, regardless of report type. 395

396 Supplemental Table 1: Summary of individual case details

A table of all included cases and factors analyzed. Author/Paper: yellow indicates this case was included in Study 1, and grey indicates it was not. Lines of improvement: green indicates this case was included in Study 2, and red indicates it was not. Time to best (months) and Worst FE VA (logMAR): orange indicates this information was

- 401 available and included in the analysis, and grey indicates it was not. Binned age: pink
- 402 indicates patients aged 18-40 (group 1), yellow indicates patients aged 41-60 (group 2),
- 403 and green indicates patients aged 61+ (group 3). History of strabismus: orange
- 404 indicates patients with a history or presence of strabismus, purple indicates patients
- 405 without a history or presence of strabismus, and grey indicates patients that were not
- 406 included in this analysis (either because this information was not available or because
- 407 the patient did not show AE VA improvement). RGC Damage: red indicates patients
- 408 with RGC damage, blue indicates patients without RGC damage, and grey indicates
- 409 patients excluded from this analysis because the RGC status was unclear.
- 410

411 **References:**

Resnick HH, Bear MF, Gaier ED. Partial Recovery of Amblyopia After Fellow Eye
 Ischemic Optic Neuropathy. *J Neuroophthalmol* 2023;43:76-81.

El Mallah MK, Chakravarthy U, Hart PM. Amblyopia: is visual loss permanent?
The British journal of ophthalmology 2000;84:952-956.

416 3. Vagge A, Shields CL, Shields JA, Pointdujour-Lim R, Schnall B. Visual
417 improvement in amblyopic eye following treatment-induced vision loss in dominant eye
418 with uveal melanoma. *The British journal of ophthalmology* 2020;104:202-207.

419 4. Rahi JS, Logan S, Borja MC, Timms C, Russell-Eggitt I, Taylor D. Prediction of 420 improved vision in the amblyopic eye after visual loss in the non-amblyopic eye. *Lancet* 421 2002;360:621-622.

422 5. Vereecken EP, Brabant P. Prognosis for vision in amblyopia after the loss of the 423 good eye. *Arch Ophthalmol* 1984;102:220-224.

Fu Z, Hong H, Su Z, Lou B, Pan CW, Liu H. Global prevalence of amblyopia and
disease burden projections through 2040: a systematic review and meta-analysis. *The British journal of ophthalmology* 2020;104:1164-1170.

427 7. Maurer D, Mc KS. Classification and diversity of amblyopia. *Vis Neurosci*428 2018;35:E012.

8. Birch EE. Amblyopia and binocular vision. *Progress in retinal and eye research*2013;33:67-84.

431 9. Holmes JM, Lazar EL, Melia BM, et al. Effect of age on response to amblyopia
432 treatment in children. *Arch Ophthalmol* 2011;129:1451-1457.

433 10. Holmes JM, Levi DM. Treatment of amblyopia as a function of age. *Vis Neurosci* 434 2018;35:E015.

Hensch TK. Critical period plasticity in local cortical circuits. *Nature reviews Neuroscience* 2005;6:877-888.
Hensch TK, Quinlan EM. Critical periods in amblyopia. *Vis Neurosci*2018;35:E014.
Spolidoro M, Sale A, Berardi N, Maffei L. Plasticity in the adult brain: lessons
from the visual system. *Exp Brain Res* 2009;192:335-341.
Loot MP. Boar MF. Cajor ED. Metaplasticity: a key to visual recovery from

441 14. Leet MP, Bear MF, Gaier ED. Metaplasticity: a key to visual recovery from 442 amblyopia in adulthood? *Curr Opin Ophthalmol* 2022;33:512-518.

- 443 15. Fong MF, Mitchell DE, Duffy KR, Bear MF. Rapid recovery from the effects of
- early monocular deprivation is enabled by temporary inactivation of the retinas. *Proceedings of the National Academy of Sciences of the United States of America*2016;113:14139-14144.
- 16. Fong MF, Duffy KR, Leet MP, Candler CT, Bear MF. Correction of amblyopia in cats and mice after the critical period. *Elife* 2021;10.
- 449 17. Duffy KR, Fong MF, Mitchell DE, Bear MF. Recovery from the anatomical effects
 450 of long-term monocular deprivation in cat lateral geniculate nucleus. *J Comp Neurol*451 2018;526:310-323.
- 452 18. Harwerth RS, Smith EL, 3rd, Crawford ML, von Noorden GK. Effects of
 453 enucleation of the nondeprived eye on stimulus deprivation amblyopia in monkeys.
 454 *Invest Ophthalmol Vis Sci* 1984;25:10-18.
- 455 19. Hendrickson A, Boles J, McLean EB. Visual acuity and behavior of monocularly 456 deprived monkeys after retinal lesions. *Invest Ophthalmol Vis Sci* 1977;16:469-473.
- 457 20. Kratz KE, Spear PD, Smith DC. Postcritical-period reversal of effects of
 458 monocular deprivation on striate cortex cells in the cat. *Journal of neurophysiology*459 1976;39:501-511.
- 460 21. Hoffmann KP, Lippert P. Recovery of vision with the deprived eye after the loss461 of the non-deprived eye in cats. *Hum Neurobiol* 1982;1:45-48.
- 462 22. Drager UC. Observations on monocular deprivation in mice. *Journal of* 463 *neurophysiology* 1978;41:28-42.
- 464 23. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an
 465 updated guideline for reporting systematic reviews. *BMJ (Clinical research ed)*466 2021;372:n71.
- 467 24. Clogg CC, Petkova E, Haritou A. Statistical methods for comparing regression
 468 coefficients between models. *American journal of sociology* 1995;100:1261-1293.
- 469 25. Brame R, Paternoster R, Mazerolle P, Piquero A. Testing for the equality of
 470 maximum-likelihood regression coefficients between two independent equations.
 471 *Journal of quantitative criminology* 1998;14:245-261.
- 472 26. Scheiman MM, Hertle RW, Beck RW, et al. Randomized trial of treatment of 473 amblyopia in children aged 7 to 17 years. *Arch Ophthalmol* 2005;123:437-447.
- 474 27. Levi DM, McKee SP, Movshon JA. Visual deficits in anisometropia. *Vision Res* 475 2011;51:48-57.
- 476 28. Woodruff G, Hiscox F, Thompson JR, Smith LK. Factors affecting the outcome of 477 children treated for amblyopia. *Eye (Lond)* 1994;8 (Pt 6):627-631.
- 29. Levartovsky S, Oliver M, Gottesman N, Shimshoni M. Factors affecting long term
- results of successfully treated amblyopia: initial visual acuity and type of amblyopia. *The*
- 480 British journal of ophthalmology 1995;79:225-228.

- 481 30. Bear MF. Bidirectional synaptic plasticity: from theory to reality. *Philos Trans R*482 Soc Lond B Biol Sci 2003;358:649-655.
- 483 31. Wu C, Hunter DG. Amblyopia: diagnostic and therapeutic options. *Am J* 484 *Ophthalmol* 2006;141:175-184.
- 485 32. Bienenstock EL, Cooper LN, Munro PW. Theory for the development of neuron
- 486 selectivity: orientation specificity and binocular interaction in visual cortex. *J Neurosci*487 1982;2:32-48.
- 488 33. Philpot BD, Espinosa JS, Bear MF. Evidence for altered NMDA receptor function
 489 as a basis for metaplasticity in visual cortex. *J Neurosci* 2003;23:5583-5588.
- 490 34. Cho KK, Khibnik L, Philpot BD, Bear MF. The ratio of NR2A/B NMDA receptor 491 subunits determines the qualities of ocular dominance plasticity in visual cortex.
- 492 Proceedings of the National Academy of Sciences of the United States of America
 493 2009;106:5377-5382.
- 494 35. Linden ML, Heynen AJ, Haslinger RH, Bear MF. Thalamic activity that drives
- 495 visual cortical plasticity. *Nature neuroscience* 2009;12:390-392.

496

Figure 1

Papers included in metaanalysis (n=23) Total number of cases (n=109) Study 1: Determine the incidence of AEVA improvement following FEVA loss Papers that include both positive and negative results (n=3) Cases included in these papers (n=42)


Cases with a timecourse to amblyopic eye improvement (n=80)

Cases with fellow eye acuity (n=55)

Cases with strabismus status (n=37)


Cases with a clear cause of vision loss (n=38)

Study 2: Describe cases with AEVA improvement Papers reporting some degree of AEVA improvement after FEVA loss (n=23) Cases in which some degree of recovery occurred (n=101)



Total=42

Figure 3








Figure 5

